LAVIPHARM S.A. NA EO 1 Total Assets
LAVIPHARM S.A. NA EO 1 total assets. Based on the latest financial reports, LAVIPHARM S.A. NA EO 1 (BXA0) holds total assets worth €125.48 Million EUR (≈ $146.70 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of LAVIPHARM S.A. NA EO 1 for how efficiently the company converts equity into cash flow.
Total Assets of LAVIPHARM S.A. NA EO 1 (2021–2024)
Total assets of LAVIPHARM S.A. NA EO 1 from 2021 to 2024. This chart illustrates how LAVIPHARM S.A. NA EO 1's total assets have evolved over time, based on quarterly financial data. See today's stock price for LAVIPHARM S.A. NA EO 1 for real-time trading data and today's change.
LAVIPHARM S.A. NA EO 1 - Asset Composition Analysis
LAVIPHARM S.A. NA EO 1 Total Assets Breakdown (December 2024)
LAVIPHARM S.A. NA EO 1 total assets breakdown as of December 2024. LAVIPHARM S.A. NA EO 1's total assets of €125.48 Million consist of 35.9% current assets and 64.1% non-current assets. Explore BXA0 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.5% |
| Accounts Receivable | €15.61 Million | 12.4% |
| Inventory | €19.46 Million | 15.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €49.68 Million | 39.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how LAVIPHARM S.A. NA EO 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LAVIPHARM S.A. NA EO 1's current assets represent 35.9% of total assets in 2024, a decrease from 49.2% in 2021.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2024, up from 3.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 5.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 39.6% of total assets.
LAVIPHARM S.A. NA EO 1 Competitors by Total Assets
Key competitors of LAVIPHARM S.A. NA EO 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.77 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
LAVIPHARM S.A. NA EO 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.24 | - |
| Quick Ratio | 0.65 | 0.79 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €5.88 Million | €9.20 Million | - |
LAVIPHARM S.A. NA EO 1 - Advanced Valuation Insights
This section examines the relationship between LAVIPHARM S.A. NA EO 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.78 |
| Latest Market Cap to Assets Ratio | 2.15 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | €125.48 Million |
| Market Capitalization | $269.79 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values LAVIPHARM S.A. NA EO 1's assets at a significant premium (2.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: LAVIPHARM S.A. NA EO 1's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below shows the annual total assets of LAVIPHARM S.A. NA EO 1 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €125.48 Million ≈ $146.70 Million |
+9.32% |
| 2023-12-31 | €114.79 Million ≈ $134.20 Million |
+0.54% |
| 2022-12-31 | €114.17 Million ≈ $133.47 Million |
+116.47% |
| 2021-12-31 | €52.74 Million ≈ $61.66 Million |
-- |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more